Rohan Palekar, 89bio CEO

With da­ta to pro­pel it in­to PhI­II, 89bio asks mar­ket for near­ly $100M to bankroll ex-Te­va drug

89bio, born out of a Te­va drug, is the lat­est to board the speed rail that takes biotechs from pos­i­tive clin­i­cal da­ta drop to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.